- Home
- ADUS vs AKRO Comparison
ADUS vs AKRO Comparison
Compare ADUS & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADUS
- AKRO
- Stock Information
- Founded
- ADUS 1979
- AKRO 2017
- Country
- ADUS United States
- AKRO United States
- Employees
- ADUS N/A
- AKRO N/A
- Industry
- ADUS Medical/Nursing Services
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- ADUS Health Care
- AKRO Health Care
- Exchange
- ADUS Nasdaq
- AKRO Nasdaq
- Market Cap
- ADUS 2.1B
- AKRO 3.9B
- IPO Year
- ADUS 2009
- AKRO 2019
- Fundamental
- Price
- ADUS $113.01
- AKRO $54.03
- Analyst Decision
- ADUS Buy
- AKRO Strong Buy
- Analyst Count
- ADUS 10
- AKRO 6
- Target Price
- ADUS $143.50
- AKRO $82.50
- AVG Volume (30 Days)
- ADUS 154.1K
- AKRO 1.7M
- Earning Date
- ADUS 08-04-2025
- AKRO 08-08-2025
- Dividend Yield
- ADUS N/A
- AKRO N/A
- EPS Growth
- ADUS 9.84
- AKRO N/A
- EPS
- ADUS 4.42
- AKRO N/A
- Revenue
- ADUS $1,211,561,000.00
- AKRO N/A
- Revenue This Year
- ADUS $23.16
- AKRO N/A
- Revenue Next Year
- ADUS $5.77
- AKRO N/A
- P/E Ratio
- ADUS $25.63
- AKRO N/A
- Revenue Growth
- ADUS 11.38
- AKRO N/A
- 52 Week Low
- ADUS $88.96
- AKRO $21.02
- 52 Week High
- ADUS $136.72
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- ADUS 52.12
- AKRO 62.21
- Support Level
- ADUS $110.64
- AKRO $53.61
- Resistance Level
- ADUS $116.66
- AKRO $56.49
- Average True Range (ATR)
- ADUS 2.95
- AKRO 2.32
- MACD
- ADUS -0.39
- AKRO -0.21
- Stochastic Oscillator
- ADUS 34.30
- AKRO 52.28
About ADUS Addus HomeCare Corporation
Addus HomeCare Corp is engaged in the provision of in-home personal care services. It operates through the segments such as Personal care segment, which is a key revenue driver, provides non-medical assistance with activities of daily living, primarily to persons who are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. The Hospice segment provides physical, emotional and spiritual care for people who are terminally ill and their families. Its Home health segment provides services that are primarily medical in nature to those individuals who may require assistance during an illness or after surgery.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.